The association of hairy cell leukemia (HCL) with other neoplasms, mainly non-Hodgkin's lymphomas, is well known. However, the simultaneous diagnosis of HCL and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is rare, with only few cases of such an association having been reported. We describe three patients with a well-characterized HCL in whom a CLL/SLL population was detected. Of note, these cases represent a significant proportion (11.5%; 95% CI: 0% to 24%) of the total number of HCL cases diagnosed in our institution during the same period of time. All three patients were treated with deoxycoformycin. They achieved a complete response of the HCL, whereas the CLL/SLL population persisted in all cases. The immunoglobulin gene rearrangement analysis, in two informative cases, suggested that the HCL and CLL/SLL populations arose from different B cell clones. This study indicates that the association of HCL and CLL/SLL might be much more frequent than previously recognized. Therefore, a large panel of monoclonal antibodies, including those necessary to detect CLL/SLL, should be employed when studying patients with HCL.
Introduction
Hairy cell leukemia (HCL) is an infrequent chronic lymphoproliferative disorder (2% of all adult leukemias), initially described by Bouroncle et al, 1 which is characterized by the infiltration of the bone marrow and the spleen by mature lymphocytes with typical cytoplasmic projections. Pancytopenia, splenomegaly, peripheral involvement and opportunistic infections are common clinical manifestations of HCL. In most instances the prognosis of patients with HCL is good, with an overall survival of around 85% at 8 years from diagnosis. [2] [3] [4] Hairy cells strongly express CD20, CD22 and monoclonal surface immunoglobulins, together with the distinctive expression of CD25, CD11c, FMC7 and CD103. Trisomy 5, structural abnormalities involving the pericentromeric regions of chromosomes 5 and 2, 1q42 abnormalities, and 14q alterations are frequently found in patients with HCL, 5 but there is no recurrent chromosomal aberration typical of this disease. Cyclin D1 gene overexpression, in absence of t (11;14) , is found in the majority of cases. 6 Although the normal counterpart of the hairy cells has not yet been identified, this disease is considered to derive from clonal post-germinal center B cells, based on the assessment of the immunoglobulin gene rearrangements 7 and the analysis of somatic hypermutation of VH genes. 8 The occurrence of second neoplasms in patients with HCL is a well-known fact. [9] [10] [11] [12] [13] [14] [15] Among them, non-Hodgkin's lym- phomas are the most frequently hematological malignancies reported. 10, 15, 16 The association of HCL and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is considered to be exceedingly rare. Thus, in an extensive computer-assisted search of the literature, only one case of transformation of CLL/SLL into HCL, 17 one case of HCL diagnosed years after the diagnosis of CLL/SLL, 18 and some cases of lymphoproliferative disorders with intermediate features between HCL and CLL/SLL [19] [20] [21] have been reported. Moreover, in the four largest studies assessing the incidence of second neoplasms in patients with HCL, including a total of 1433 patients, no case of CLL/SLL has been described. [12] [13] [14] [15] Since 1991, all the cases of HCL diagnosed in our center were systematically screened for the presence of additional B cell populations using an extensive panel of monoclonal antibodies. Using this approach, three patients with the simultaneous existence of a HCL and CLL/SLL were identified. The aim of the present study is to describe the clinical, morphologic, immunophenotypic and molecular features of these cases and to comment on the association between HCL and CLL/SLL.
Patients and methods

Patients and treatment
Between 1991 and 1997, 26 consecutive patients were diagnosed with HCL in our institution according to standard clinical, morphological and phenotypic criteria. 22 During the same period of time, 270 patients were diagnosed with CLL/SLL. 23, 24 In all cases the immunophenotype of the neoplasic cells was studied by cytofluorometry as described below. Phenotypic and molecular analysis from peripheral blood and bone marrow samples were performed at diagnosis and during the course of the disease. Most patients with HCL were treated with deoxycoformycin (DCF) at a dose of 4 mg/m 2 every 2 weeks, until maximal response or for a minimum of six cycles in case of treatment failure. Response was evaluated according to conventional criteria.
3,25
Immunophenotypic analysis
Peripheral blood or bone marrow samples were used to assess the membrane phenotype of lymphocytes. Briefly, 5 × 10 5 cells were incubated (15 min) with the appropriate amounts of monoclonal antibodies using double or triple color combinations, followed by red cell lyses using FACS lysing solution. Stained samples were acquired in a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), and analyzed using the Paint-a Gate Pro software (Becton Dickinson). The reactivity against T cell antigens (at least CD3, CD4, CD5, CD8), B cell antigens (at least CD19, CD22, CD20, kappa and lambda light chain), and other antigens (at least CD11c, CD23, CD25, CD103) was analyzed. When required, immunohistochemical analysis was performed in bone marrow biopsies using CD79a and CD5 antibodies in order to ascertain CLL/SLL infiltrates.
Immunoglobulin gene rearrangement
High molecular weight DNA was extracted from mononuclear cells isolated by Ficoll gradient according to standard procedures. 26 Consensus primers for the framework 3 (FR3) portion of the variable region and of the 3Ј portion of the joining region of the immunoglobulin heavy chain gene, based on previously published studies, 26 were used to amplify the CDR3 region. The reaction mixture of PCR contained 30 pmols of each primer, 200 mM of each dNTPs, 2.5 mM MgCl 2 and 1.25 U of High Expand Fidelity (Roche Diagnostics, Mannheim, Germany) and 1 g of template. The reaction consisted of 40 cycles of a denaturation step at 94°C for 1 min (10 min first cycle), an annealing step at 55°C for 2 min and an extension step for 1 min at 72°C (10 min last cycle). Amplified DNA was electrophoresed on an acrylamide-bis (19:1) gel 5% and was stained using ethidium bromide and visualized under UV.
Literature search
A literature search of the period January 1966 to July 2001 was performed using the Pub Med Service, National Library of Medicine -National Center for Biotechnology information (www.ncbi.nlm.nih.gov/) USA. Key words consulted were: hairy cell leukemia and chronic lymphocytic leukemia, hairy cell leukemia, hairy cell leukemia and treatment.
Results
Three of the 26 patients with HCL (11.5%; 95% CI: 0% to 24%) showed a concomitant B cell population consistent with B cell CLL/SLL. The main clinical, immunophenotypic and molecular characteristics of these patients are detailed in Table 1 and briefly described below. 
Leukemia
Patient 1
A 59-year-old man was referred to our center with a palpable splenomegaly and retroperitoneal lymph nodes. The WBC count was 9.53 × 10 9 /l (60% lymphocytes, the great majority with a hairy cell appearance). The bone marrow aspirate showed the presence of 54% hairy cells. A bone marrow biopsy revealed interstitial infiltration by two distinct lymphocyte subtypes: (1) medium-sized lymphocytes, with a round nuclear profile and fine chromatin, widely separated from each other by their cytoplasm, (2) small lymphocytes, with round nucleus and mature chromatin; there was a marked increase in reticulin fibers and the small lymphocyte infiltrates were positive for CD79a and CD5 (Figure 1) +/− , and lambda chain restriction) (Figure 2-1) .
The patient was treated with DCF. After treatment, a complete response was documented. However, both hairy cell and CLL/SLL immunophenotypic markers were observed in the peripheral blood. Six years after diagnosis the patient presented with clinical manifestations related to the CLL/SLL, lymphocytosis (20 × 10 9 /l), thrombocytopenia and a palpable splenomegaly. The presence of both B cell lymphocytic populations was again confirmed by morphologic and immunophenotyping methods (53% of CLL/SLL lymphocytes and 2% of hairy cells in the peripheral blood). After completing treatment with 2-chlorodeoxyadenosine, the hematological parameters normalized and the immunophenotypic analysis detected only the presence of the CLL/SLL population. The PCR analysis performed at that time showed a single heavy chain immunoglobulin gene (JH) band.
Patient 2
A 49-year-old man was referred to our center because of pancytopenia found in a routine analysis. The physical examination revealed palpable splenomegaly at 5 cm below the costal margin. The hemoglobin level was 97 g/l, the WBC count 1.7 × 10 9 /l (89% lymphocytes) and the platelet count 69 × 10 9 /l. A sternal bone marrow aspirate was hypercellular with 41% hairy cells. A bone marrow biopsy revealed a diffuse infiltration by cells typical of HCL and a moderate increase in reticulin fibers. Peripheral blood immunophenotypic analysis detected 5% cells with a characteristic HCL phenotype, and in 12% a CLL/SLL phenotype (Figure 2-2) . The bone marrow cytogenetic study was normal in the 20 metaphases analyzed. The PCR analysis of the heavy chain immunoglobulin gene (J H ) pattern in peripheral blood lymphocytes showed two differentiated clonal bands. The patient was treated with six cycles of DCF. After completing such treatment, the cytological and immunophenotypic analysis disclosed only the CLL/SLL population, and the molecular analysis showed a single monoclonal band. One year later, coincidentally with the immunophenotypic detection of minimal HCL population, two monoclonal bands appeared in the VH analysis of the bone marrow sample (Figure 3) .
Patient 3
A 48-year-old man previously diagnosed with HCL at another center, where he was treated with DCF, was referred to us 1 year later for evaluation. At that time the WBC count was 51 × 10 9 /l, with 75% of lymphocytes with typical features of CLL/SLL. Peripheral blood and bone marrow immunophenotypic analysis was also characteristic of CLL/SLL with a lambda clonal light chain restriction. Moreover, in 1% of bone marrow lymphocytes a typical HCL phenotype was found (Figure 2-3) . The patient achieved a clinical response after treatment with fludarabine combined with cyclophosphamide and mitoxantrone. However, the immunophenotypic and molecular studies demonstrated the persistence of both B cell populations. The patient underwent an autologous peripheral stem cell transplantation, and 1 year later neither CLL/SLL nor HCL are detectable.
Discussion
The association of HCL and CLL/SLL is considered to be rare. To challenge this concept we report three patients with HCL in whom a population of lymphocytes with the classical immunophenotypic features of CLL/SLL was detected. These cases represented a noteworthy percentage (11.5%), albeit with extremely wide 95% CI (0% to 24%), of the total number of HCL cases diagnosed in our institution during the same period of time. Although the patients reported presented with clinical and morphological characteristics of HCL, the concurrent diagnosis was made after an accurate morphological and immunophenotypical analysis of the B lymphocyte population in peripheral blood or bone marrow. Furthermore, after receiving treatment for the HCL, two of the patients developed clinical manifestations related to the progression of the CLL/SLL population, whereas the HCL remained, in all cases, silent.
The coexistence of two different lymphoproliferative disorders in the same patient is a well-known situation, most of the cases being transformations from a low-grade into highgrade lymphoma. In this regard, HCL can also evolve into aggressive lymphoma, mimicking the so-called Richter's syndrome in CLL/SLL. 10, 27 The association of HCL with other lymphoproliferative disorders is unusual. Thus, only a few cases of HCL associated with Hodgkin's disease, 11, 12 multiple myeloma 15 or CLL/SLL 17, 18 have been described. In a computer-assisted literature search, we have identified only two reports describing the association of CLL/SLL and HCL. 18, 19 In these cases the HCL population was detected several years after the diagnosis and treatment of the CLL/SLL. Conversely, in our patients both populations were detected at the same time. It is worth emphasizing the significant prevalence of this association in our series of HCL (11%). This could be due, in part, to the large panel of monoclonal antibodies used for the diagnosis of chronic lymphoproliferative disorders in our institution, and to the refinement and accuracy of the phenotype techniques. On the other hand, a referral center bias cannot be excluded. Nevertheless, the coexistence of HCL and CLL/SLL seems to be a unique phenomenom since, among 270 patients diagnosed with CLL/SLL during the same period of time in whom the same panel of monoclonal antibodies was used, none was found to have HCL. In any case, the high prevalence found in this series should be verified in a larger panel of HCLs.
In an attempt to explain the coexistence of HCL and CLL/SLL, some hypotheses can be formulated. Patients with CLL/SLL have an impaired immune surveillance that might contribute to the development of second neoplasms. 28, 29 Likewise, a trend for the development of second malignancies has been described in HCL. 12, 15, 16 Based on phenotypic and molecular studies, it is now well established that HCL derives from germinal or post-germinal center cells. 30 Thus, hairy cells have the phenotype of activated normal B cells (CD22, CD25 and CD40 ligand). Moreover, 'hairy cell restricted antigens', such as CD11c and CD103, have been associated with the activation of certain lymphoid and non-lymphoid cell types. 25 From the molecular standpoint, hairy cells have somatic Leukemia mutations of the immunoglobulin variable region genes, 8 a hallmark of a germinal center origin. 31, 32 Conversely, about 50% of CLL/SLL derive from post-germinal center CD5 +
CD27
+ memory B cells, 33 whereas the remaining CLL/SLL originate in CD5 + pre-germinal cells. 33 Of note, CLL/SLL cells can be differentiated under a variety of stimuli and, upon culture treated with phorbol ester (TPA), can acquire the phenotype of HCL activated cells. 34 In this setting, the presence of the same immunoglobulin gene rearrangement in two different lymphoproliferative disorders, although not definitive, argues strongly in favor of a common precursor origin. One of the two previously reported cases associating CLL/SLL and
Figure 3
Ethidium bromide staining of the PCR product corresponding to the immunogobulin rearrangement analysis of the patient 2. At diagnosis (a) the PCR analysis showed two bands. After treatment (b), cytofluorometric methods did not detect any HCL population, and the PCR exhibits only one band.
HCL had a unique immunoglobulin gene rearrangement, 17 whereas in the other one the appearance of the HCL was followed with the appearance of additional bands, with this suggesting a different clonal origin. 18 Among the cases reported herein, two of them (patients 2 and 3) presented two different immunoglobulin gene rearrangements, a finding that argues for a separate clonal origin. In the remaining case, there was a unique band of rearrangement, but the result was not conclusive since, at that time, the HCL population was not detectable.
In conclusion, HCL can coexist with the diagnosis of CLL/SLL. This observation, which should be confirmed in other prospective studies, emphasizes the advantages of utilizing a large panel of monoclonal antibodies in the diagnosis of chronic lymphoproliferative disorders.
